腫瘤是威脅我國居民生命健康最重要的一類疾病，每年有接近400萬新發腫瘤患者。其中的晚期腫瘤患者，缺乏有效治療手段，只能靠用藥維持生命。但我國的現狀是一方面是患者對前沿最新抗腫瘤藥物的需求，另一方面是前沿新藥帶來的沉重經濟負擔?；颊咭詤⒓优R床試驗的形式得到治療是一種滿足制藥企業和腫瘤患者雙方利益的形式，在國外已廣泛開展，但國內患者對臨床試驗相對陌生，因有所顧慮而未充分接納這種形式的治療。
為打破腫瘤患者和制藥企業的隔閡，實現雙方的獲益。愛渡公司從成立以來全面啟動抗腫瘤藥物臨床試驗志愿者招募服務并同步拓展自媒體/新媒體領域，創立“ai幫幫”和“ai幫幫之聲”品牌，分別承擔志愿者招募和腫瘤醫學知識科普的職能。
愛渡公司向制藥企業提供的志愿者招募服務與傳統模式不同，通過向患者傳遞專業的醫學知識和最新的醫藥產業信息打破患者和醫療服務提供方的信息不對等，幫助腫瘤患者理解和接納臨床試驗，從而主動選擇臨床試驗。愛渡公司在患者參加臨床試驗的準備階段，提供免費的代理服務，減少腫瘤患者額外的負擔。
迄今為止，愛渡公司已與復星醫藥、復宏漢霖、信達生物、基石藥業、百濟神州、和黃藥業、康方天成、海和生物、泰州翰中、金賽藥業、諾誠健華、奧鴻藥業、嘉和生物藥業等多家擁有抗腫瘤藥物獨立研發能力的內資制藥企業達成合作。項目涵蓋多種實體瘤(如肺癌、食管癌、結直腸癌、胃癌、膽道癌、肝癌、乳腺癌、卵巢癌、宮頸癌、甲狀腺癌、頭頸癌、黑色素瘤、神經內分泌瘤等)、淋巴瘤(經典霍奇金淋巴瘤、成熟B細胞淋巴瘤、NK/T細胞淋巴瘤、外周T細胞淋巴瘤等)和血液腫瘤(骨髓增生異常綜合征、急性髓系白血病等)。旗下品牌“ai幫幫”和“ai幫幫之聲”已成功覆蓋10萬以上的精準腫瘤用戶及家屬，踐行了愛渡公司的成立初衷：為患者提供治療的新希望，為醫生積累最新藥物使用經驗，為制藥企業加速臨床試驗進度。
Shanghai Aidu Medical Technology Co., Ltd. (hereinafter referred to as Aidu Medical) was established in March 2018, focusing on the recruitment of clinical trial participants of new anti-tumor drugs, and wascommitted to be the best partner for Chinese innovative pharmaceutical companies of anti-tumor drugs.
In order to break the gap between cancer patients and pharmaceutical companies and realize the benefits of both parties, Aidu has launched a comprehensive recruitment of antitumor drug clinical trial volunteer recruitment services since its establishment, and expanded the self-media/new media field simultaneously, creating "ai_jiuzhu" and "aibbzs" brand respectively, which are responsible for volunteer recruitment and oncology knowledge popularization.
So far, Aidu Medical has reached cooperation with a number of domestic-funded pharmaceutical companies with independent R&D capabilities of anti-tumor drugs, including Fosunpharma, Henlius, Innovent, CStone Pharmaceuticals, BeiGene, Hutchison Pharmaceuticals, Akeso Biopharma, HaiHe Biopharma, Taizhou Hanzhong Biomedical, GenSci Biopharma, InnoCare Pharmaceuticals , Avanc Pharmaceuticals, Jiahe Biological Pharmaceuticals, ect. The brands of "ai_jiuzhu" and "aibbzs" have successfully covered more than 100,000 precision tumor users and their families, fulfilling the original intention of Aidu Medical: to provide new hopes for cancer patients, to accumulate new drug using experience for doctors and to accelerate the progress of clinical trials for pharmaceutical companies.
